The short answer
Ganoderma has not been shown to change heparin absorption or cause added bleeding. A trial of Ganoderma lucidum found no impairment of measured hemostasis, but it did not include heparin and cannot cover every Ganoderma product.
What this answer covers
Genus-level Ganoderma entry; the studied G. lucidum capsules are only one preparation. Extracts, spores and other species must be distinguished.
- Supplement or preparation
- Ganoderma
- Medication ingredient
- heparin
What the trial found
Forty healthy volunteers received G. lucidum capsules or placebo for four weeks. Platelet and global clotting measurements remained normal and did not differ significantly between groups. This challenges extrapolation from earlier laboratory platelet-inhibition findings.
Normal tests are not universal safety proof
The trial assessed hemostatic tests in healthy people, not actual bleeding during heparin therapy or surgery. Its authors’ inference about surgical safety should not be treated as an observed combination outcome.
Absorption is not the demonstrated mechanism
The heparin label states that heparin is not absorbed through the digestive tract and is given by injection. No reviewed evidence shows that oral Ganoderma changes injected heparin exposure or anticoagulant effectiveness.
Confirm the mushroom product
Tell the heparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed heparin yourself. The genus name alone does not identify the studied species, part or extract, and no safe dosing gap has been established.
Evidence and practical considerations
Side effects & toxicity
No exact-pair bleeding evidence; the G. lucidum trial had null hemostatic findings and is indirect for the broad genus entry.
- Exact scope
- Genus-level Ganoderma entry; the studied G. lucidum capsules are only one preparation. Extracts, spores and other species must be distinguished. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40 healthy volunteers, 20 per group.
No significant between-group differences in measured platelet and global hemostatic tests; results remained within normal ranges.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Healthy volunteers only; no heparin exposure or surgical bleeding outcome. Genus-level Ganoderma entry is not a verified match to every product.
Research assessment: · Open full citations ↗
Absorption & effectiveness
No measured change in injected heparin action or exposure. Heparin does not rely on gastrointestinal absorption; laboratory mushroom effects cannot establish a pharmacokinetic interaction.
- Exact scope
- Genus-level Ganoderma entry; the studied G. lucidum capsules are only one preparation. Extracts, spores and other species must be distinguished. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40 healthy volunteers, 20 per group.
No significant between-group differences in measured platelet and global hemostatic tests; results remained within normal ranges.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Healthy volunteers only; no heparin exposure or surgical bleeding outcome. Genus-level Ganoderma entry is not a verified match to every product.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact-pair article preserving route, formulation, clinical-outcome and laboratory-endpoint distinctions. | |
| Research summary published |
Article revision: cff6fc464332a1bd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.